Table 1.
Macrophage polarization related pathways, target genes and exosome contents summarized in this review.
| Author | Year | Tumor | M1/M2 | Exosome cargos | Target genes | Pathways |
|---|---|---|---|---|---|---|
| Su et al. [136] | 2016 | PDAC | M2 | miR-155, miR-125b | NA | NA |
| Wang et al. [30] | 2018 | M2 | miR-301a-3p | PTEN | PI3K/AKT/mTOR | |
| Linton et al. [154] | 2018 | M2 | Arachidonic acid | NA | NA | |
| Li et al. [113] | 2018 | HCC | M2 | LncRNA TUC339 | CXCR | CRSa |
| Yin et al. [60] | 2019 | M2 | miR-146-5p | SALL4 | STAT3 | |
| Wang et al. [145] | 2021 | M2 | circ-0074854 | NA | NA | |
| Wang et al. [143] | 2022 | M2 | LncRNA HMMR-AS1, miR-147a | ARID3A | NA | |
| Liang et al. [114] | 2019 | CRC | M2 | LncRNA RPPH1 | TUBB3 | NA |
| Zhao et al. [31] | 2020 | M2 | miR-934 | PTEN, CXCL13, CXCR5 | PI3K/AKT, NFκB/p65 | |
| Yang et al. [44] | 2021 | M2 | miR-106b | PDCD4 | PI3Kγ/Akt/mTOR | |
| Lu et al. [116] | 2020 | EC | M2 | circ-0048117 | TLR4 | NA |
| Song et al. [38] | 2021 | M2 | miR-21-5p | PTEN | PI3K/AKT/STAT6 | |
| Wu et al. [102] | 2016 | GC | M1 | NA | NA | NFκB |
| Xin et al. [144] | 2021 | M2 | LncRNA HCG18, miR-875-3p | KLF4 | NA | |
| Ham et al. [80] | 2018 | BC | M2 | Gp130 | IL-6 | STAT3 |
| Moradi et al. [141] | 2020 | M1 | miR-130, miR-33 | NA | NA | |
| Moradi et al. [142] | 2021 | M1 | miR-130 | NA | NA | |
| Xun et al. [124] | 2021 | M2 | miR-138-5p | KDM6B | NA | |
| Dong et al. [97] | 2021 | M1 | PTPRO | NA | STAT3/STAT6 | |
| Lu et al. [47] | 2022 | M2 | circ-0001142 | PIK3CB | PI3K/AKT | |
| Ying et al. [53] | 2016 | EOC | M2 | miR-222-3p | SOCS3 | SOCS3/STAT3 |
| Chen et al. [137] | 2017 | M2 | miR-940 | NA | NA | |
| Chen et al. [54] | 2018 | M2 | miR-21-3p, miR-125b-5p, miR-181d-5p | SOCS4/5 | SOCS/STAT3 | |
| Xiao et al. [138] | 2020 | EC | M2 | miR-21 | NA | NA |
| Qian et al. [88] | 2019 | Glioma | M2 | miR-1246 | TERF2IP | NF-κB, STAT3 |
| Xu et al. [84] | 2021 | M2 | miR-155-3p | IL-6, CREB3 | STAT3 | |
| Tong et al. [129] | 2020 | HNSCC | M2 | miR-9 | PPARδ | NA |
| Cai et al. [57] | 2019 | OSCC | M2 | miR-29a-3p | SOCS1 | SOCS1/STAT6 |
| Pang et al. [110] | 2020 | M2 | CMTM6 | NA | ERK1/2 | |
| Ono et al. [146] | 2020 | M2 | CDC37, HSP90α, HSP90β | NA | NA | |
| Chen et al. [46] | 2021 | LC | M2 | circ-FARSA | PTEN | PI3K/AKT |
| Liu et al. [111] | 2021 | M2 | miR-770 | MAP3K1 | MAPK | |
| Chen et al. [93] | 2021 | M2 | miR-19b-3p, LINC00273 | PTPRD, NEDD4, RBMX, TEAD4 | STAT3, Hippo/YAP | |
| Cheng et al. [153] | 2021 | Osteosarcoma | M2 | Tim-3 | NA | NA |
| Lin et al. [41] | 2019 | Bladder cancer | M2 | miR-21 | PTEN | PI3K/AKT/STAT3 |
| Jiang et al. [42] | 2021 | M2 | miR-92b-3p, miR-1231-5p | PTEN | AKT/STAT3/6 | |
| Zhao et al. [95] | 2021 | GBC | M2 | Leptin | NA | STAT3 |
a
CRS: Cytokine receptor signaling; NA: NONE.